natgillin/translations-raw huggingface dataset:
Ketoconazole/Tenofovir disoproxil fumarate
ketokonazol/dizoproksiltenofovirijev fumarat
Ketoconazole: AUC: ↑2.1-fold Cmax: ↑1.1-fold t1/2: ↑ 4-fold
Ketokonazol: AUC: ↑2,1-krat Cmax: ↑1,1-krat t1/2: ↑ 4-krat
Ketoconazole: AUC: ↓ 24%
ketokonazol: AUC: ↓ 24
Ketoconazole: AUC: ↓0.28-fold Cmax: ↓0.56-fold
Ketokonazol: AUC: ↓ 0,28-krat Cmax: ↓ 0,56-krat
Ketoconazole: Cmax  25% Ketoconazole: AUC  2.69- fold.
ketokonazol: Cmax  25% ketokonazol: AUC  2.69-krat.
Ketoconazole: co-administration for 6 days of bosentan 62.5 mg twice daily with ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan approximately 2-fold.
Ketokonazol: pri 6-dnevni sočasni uporabi bosentana v odmerku 62,5 mg dvakrat na dan 6 dni in ketokonazola, močnega zaviralca CYP3A4, se je plazemska koncentracija bosentana zvišala približno za dvakrat.
Ketoconazole: co-administration for 6 days of bosentan 62.5 mg twice daily with ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan approximately 2-fold.
Ketokonazol: pri 6-dnevni sočasni uporabi bosentana v odmerku 62,5 mg dvakrat na dan in ketokonazola, močnega zaviralca CYP3A4, se je plazemska koncentracija bosentana zvišala približno za dvakrat.
Ketoconazole: Ketoconazole 400 mg once daily for 7 days with a single concomitant dose of edoxaban 60 mg on Day 4, increased edoxaban AUC and Cmax by 87% and 89%, respectively.
Ketokonazol: ketokonazol 400 mg enkrat na dan 7 dni z enkratnim sočasnim odmerkom edoksabana 60 mg 4. dne je zvečal AUC in Cmax edoksabana za 87 % oziroma 89 %.
ketonazole, a medicine used to treat fungal infections.
ketokonazol, zdravilo za zdravljenje glivičnih okužb,
Ketones measured in urine
v urinu izmerjeni ketoni
ketosis;
ketoza,
Kexxtone 32.4g continuous-release intraruminal device for cattle.
Kexxtone 32,4 g intraruminalni sistem s kontinuiranim sproščanjem za govedo
Key ACR results for the Simponi 50 mg dose at weeks 14, 24 and 52 for GO-FORWARD, GO-AFTER and GO-BEFORE are shown in Table 2 and are described below.
Ključni rezultati so prikazani v preglednici 6 in opisani spodaj.
key aspects of the DMC charter, has to be agreed before initiation of the study.
O protokolu študije, vključno z bistvenimi vidiki listine DMC, se je treba dogovoriti pred začetkom študije.
Key baseline characteristics included: 58% of patients were male, median age was 55 years (range 23 to 88 years), 60% had metastatic melanoma stage M1c and the proportion of patients with elevated LDH was 46.3% in the cobimetinib plus vemurafenib arm and 43.0% in the placebo plus vemurafenib arm.
Ključne značilnosti so bile: 58 % bolnikov je bilo moških, mediana starosti je bila 55 let (razpon: od 23 do 88 let), 60 % je imelo metastatski melanom v stadiju M1c, delež bolnikov z zvišanjem LDH pa je bil v skupini s kobimetinibom in vemurafenibom 46,3 % ter v skupini s placebom in vemurafenibom 43,0 %.
Key differences in the design of the packages and the prefilled pen devices;
ključne razlike v oblikovanju pakiranja in napolnjenih injekcijskih peresnikov,
Key efficacy outcomes from GO-AHEAD at week 16
Ključni izidi učinkovitosti v študiji GO-AHEAD v 16. tednu
Key efficacy outcomes from GO-RAISE.
Bistveni rezultati glede učinkovitosti iz študije GO-RAISE
Key efficacy outcomes from GO-REVEAL
Bistveni rezultati glede učinkovitosti iz študije GO-REVEAL
Key efficacy outcomes from PURSUIT - Induction and PURSUIT - Maintenance
Ključni izidi učinkovitosti iz študij PURSUIT - Induction in PURSUIT - Maintenance
Key efficacy outcomes from the controlled portions of GO-FORWARD, GO-AFTER and GO-BEFORE.
Bistveni rezultati glede učinkovitosti iz nadzorovanih delov študij GO-FORWARD, GO-AFTER in GO-BEFORE
Key efficacy outcomes from the controlled portions of GO-FORWARD, GO-AFTER and GO-BEFORE.
Ključni izidi učinkovitosti v študiji GO-AHEAD v 16. tednu
Key efficacy outcomes from the PsA001 clinical trial are shown in Table 9.
Ključni rezultati glede učinkovitosti pri kliničnem preskušanju PsA001 so prikazani v Preglednici 9.
Key efficacy results at 48 weeks for patients 12 – 18 years of age who took capsule
Ključni izsledki o učinkovitosti po 48 tednih za bolnike od 12 do 18 let, zdravljene s kapsulami
Key efficacy results at 48 weeks for patients 2 - <12 years treated with Aptivus oral solution
Ključni izsledki o učinkovitosti po 48 tednih za bolnike od 2 do < 12 let, zdravljene s peroralno raztopino Aptivus
Key elements of the Healthcare Professional FAQ Brochure (Q&A format) intended for Healthcare Providers treating adolescent patients with bipolar mania:
Ključni elementi brošure s pogostimi vprašanji za zdravstvene delavce (v obliki vprašanj in odgovorov), ki je namenjena za distribucijo zdravstvenim delavcem, ki zdravijo mladostnike z bipolarno manijo:
Key elements of the Patients/Caregiver Information Brochure:
Ključni elementi brošure z informacijami za bolnike/skrbnike:
Key elements of the physician educational material:
Ključni elementi izobraževalnega gradiva za zdravnike:
Key elements to be included
Ključni elementi, ki naj bodo zajeti
Key elements to be included in the educational material for healthcare professionals:
Ključni elementi, ki morajo biti vključeni v izobraževalno gradivo za zdravstvene delavce:
Key eligibility criteria for patients with metastatic adenocarcinoma of the pancreas in the NAPOLI-1 clinical study were Karnofsky Performance Status (KPS) ≥ 70, normal bilirubin level, transaminase levels ≤ 2.5 times the ULN or ≤ 5 times the ULN for patients with liver metastases and albumin ≥ 3.0 g/dl.
Glavna merila primernosti bolnikov z metastatskim adenokarcinomom trebušne slinavke za vključitev v klinično študijo NAPOLI-1 so bila stanje zmogljivosti po Karnofskyju (KPS) ≥ 70, normalna raven bilirubina, raven transaminaz ≤ 2,5-krat ULN ali ≤ 5-krat ULN za bolnike z jetrnimi metastazami in albumin ≥ 3,0 g/dl.
Key features of the design of the package and pre-filled pen device
Ključne lastnosti zasnove pakiranja in napolnjenega peresnika.
Key features of the design of the package and prefilled pen device
Ključne lastnosti zasnove pakiranja in napolnjenega peresnika.
Key findings from SMART by inhaled steroid use at baseline: secondary endpoints
Ključne ugotovitve študije SMART pri uporabi inhalacijskega kortikosteroida v izhodišču: sekundarni opazovani dogodki
Key findings from SMART: primary endpoint
Ključne ugotovitve študije SMART: primarni opazovani dogodek
Key outcome measures are summarised in Table 2 (RESTORE and Extension) and Figure 2 (RESTORE).
Glavna merila izidov so prikazana v preglednici 2 (študija RESTORE in podaljšanje te študije) in na sliki 2 (študija RESTORE).
Key outcome measures from BRAVO and CRUISE are summarised in Table 4 and Figures 3 and 4.
Glavna merila izidov v študijah BRAVO in CRUISE so prikazana v preglednici 4 in na slikah 3 in 4.
Key outcome measures from BRIGHTER and CRYSTAL are shown in Table 5.
Glavni izidi meritev v študijah BRIGHTER in CRYSTAL so prikazana v preglednici 5.
Key primary endpoints
Ključni primarni opazovani dogodek
Key results for the 50 mg dose at weeks 14 and 24 are shown in table 4 and described below.
Ključni rezultati za 50 mg odmerek v 14. tednu in 24. tednu so prikazani v Preglednici 4 in opisani v nadaljevanju.
Key safety messages have to be included in the educational pack for all indications.
Izobraževalno gradivo mora vsebovati ključna sporočila o varnosti za vse indikacije.
Key Secondary Efficacy Endpoint (CV death / MI / stroke) §
Ključni sekundarni opazovani dogodki učinkovitosti (CV smrt/MI/ možganska kap) §
Key secondary efficacy outcome measures were investigator-assessed ORR and PFS.
Ključni sekundarni merili učinkovitosti sta bili raziskovalčeva ocena deleža objektivnega odziva in preživetje brez napredovanja bolezni.
Key secondary efficacy outcome measures were investigator-assessed PFS and objective response rate (ORR).
Ključni sekundarni merili učinkovitosti sta bili raziskovalčeva ocena preživetja brez napredovanja bolezni (PFS - progression-free survival) in delež objektivnega odziva (ORR - objective response rate).
Key secondary endpoints
Ključni sekundarni cilji
Key Secondary Endpointsa, f,
Ključni sekundarni opazovani dogodkia, f
Key signs and symptoms of intravitreal injection related adverse events including endophthalmitis, increased intraocular pressure, retinal injury, intraocular haemorrhage, traumatic cataract, hypersensitivity and injection of excess volume
ključnih znakih in simptomih neželenih dogodkov, ki so povezani z intravitrealnim injiciranjem in vključujejo endoftalmitis, zvišanje očesnega tlaka, poškodbo mrežnice, krvavitev v oko, travmatsko katarakto, preobčutljivost in injiciranje odvečnega volumna
Key signs and symptoms of intravitreal injection related adverse events including endophthalmitis, increased intraocular pressure, retinal pigment epithelial tear and cataract
ključne znake in simptome neželenih učinkov, povezanih z intravitrealnim injiciranjem tj. endoftalmitis, povišan intraokularni tlak, zatrganje pigmentnega epitelija mrežnice in katarakta
Key signs and symptoms of IVT injection related adverse events including increased intraocular pressure, glaucoma, ocular hypertension, cataract, traumatic cataract related to injection technique, vitreous detachment, vitreous haemorrhage, endophthalmitis, retinal detachment, retinal tear, device dislocation and implant misplacement
ključne znake in simptome neželenih učinkov, povezanih z intravitrealnim injiciranjem, vključno z zvišanim očesnim tlakom, glavkomom, očesno hipertenzijo, katarakto, poškodbeno katarakto v povezavi s tehniko injiciranja, odstopom steklovine, vitrealno krvavitvijo, endoftalmitisom, odstopanjem očesne mrežnice, raztrganino očesne mrežnice, premikom pripomočka in vstavitvijo vsadka v nepravilen položaj,
Key signs and symptoms of myocardial infarction, VTE and serious skin reactions.
glavne znake in simptome miokardnega infarkta, venske trombembolije in hudih kožnih reakcij,
Key signs and symptoms of serious adverse events
Ključni znaki in simptomi resnih neželenih učinkov
Key signs and symptoms of serious adverse events including endophthalmitis, intraocular pressure increased, retinal pigment epithelial tear and cataract
ključne znake in simptome resnih neželenih učinkov tj. endoftalmitisa, povišanega intraokularnega tlaka, zatrganja pigmentnega epitelija mrežnice in katarakte
Key signs and symptoms of serious adverse reactions
Bistvene znake in simptome resnih neželenih učinkov
Key: 1GSS to OBT: Genotypic Sensitivity Score to Optimised Background.
Legenda: 1GSS pri OBT: rezultat genotipske občutljivosti (GSS) pri optimiziranem osnovnem zdravljenju (OBT).
Key: 1GSS to OBT: Genotypic Sensitivity Score to Optimised Background.
Legenda: 1GSS pri OBT: rezultat genotipske občutljivosti (GSS-Genotypic Sensitivity Score) pri optimiziranem osnovnem zdravljenju (OBT- Optimised Background).
Key: Grey matter – f frontal and ac anterior cingulate, pc posterior cingulate and precuneus, lt lateral temporal, tp temporo-parietal and in insula and and s striatum.
Gesla: siva možganovina - f frontalni in ac anteriorni cingulatni, pc posterioni cingulati in prekuneusni, lt stranski temporalni , tp temporo-parietalni in in insula in s striatum.
Key: HoFH = homozygous familial hypercholesterolaemia; QM = once monthly; a nominal p value <0.001 when compared with placebo; b p value < 0.001 when compared with placebo.
Legenda: HoDH = homozigotna družinska hiperholesterolemija; a nominalna vrednost p < 0,001 v primerjavi s placebom, b vrednost p < 0,001 v primerjavi s placebom.
Key: OLE = open-label extension, N (n) = Number of evaluable patients (N) and patients with observed LDL values at specific scheduled visit (n) in the severe familial hypercholesterolaemia interim analysis set
Legenda: N (n) = število ocenljivih bolnikov (N) in bolnikov z opaženimi vrednostmi LDL na posameznem načrtovanem obisku (n) v naboru podatkov za vmesno analizo pri bolnikih s hudo družinsko hiperholesterolemijo
Key: Q2W = once every 2 weeks, QM = once monthly, HMD = Primary hypercholesterolaemia and mixed dyslipidaemia,a p value < 0.05 when compared with ezetimibe, b p value < 0.001 when compared with ezetimibe, c nominal p value < 0.001 when compared with ezetimibe.
Legenda: HMD = primarna hiperholesterolemija in mešana dislipidemija,a vrednost p < 0,05 v primerjavi z ezetimibom, b vrednost p < 0,001 v primerjavi z ezetimibom, c nominalna vrednost p < 0,001 v primerjavi z ezetimibom.
Key: Q2W = once every 2 weeks, QM = once monthly, HMD = Primary hypercholesterolaemia and mixed dyslipidaemia; HeFH = Heterozygous familial hypercholesterolaemia; a p value < 0.05 when compared with placebo. b p value < 0.001 when compared with placebo.
Legenda: HMD = primarna hiperholesterolemija in mešana dislipidemija; HeDH = heterozigotna družinska hiperholesterolemija, a vrednost p < 0,05 v primerjavi s placebom. b vrednost p < 0,001 v primerjavi s placebom.
Key:  reduced, ↑ increased,  unchanged, ↑↑ markedly increased
Legenda:  zmanjšano, ↑ povečano,  nespremenjeno, ↑↑ izrazito povečano
KEYNOTE-002: Controlled trial in melanoma patients previously treated with ipilimumab
KEYNOTE-002: kontrolirano preskušanje pri bolnikih z melanomom, predhodno zdravljenih z ipilimumabom
KEYNOTE-006: Controlled trial in melanoma patients naïve to treatment with ipilimumab
KEYNOTE-006: kontrolirano preskušanje pri bolnikih z melanomom, ki predhodno niso bili zdravljeni z ipilimumabom
KEYNOTE-010: Controlled trial in NSCLC patients previously treated with chemotherapy
KEYNOTE-010: kontrolirano preskušanje pri bolnikih z NSCLC, predhodno zdravljenih s kemoterapijo
KEYTRUDA as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.
Zdravilo KEYTRUDA je v obliki monoterapije indicirano za zdravljenje napredovalega (neoperabilnega ali metastatskega) melanoma pri odraslih.
KEYTRUDA can cause harm or death to your unborn baby.
Zdravilo KEYTRUDA lahko škoduje nerojenemu otroku ali povzroči njegovo smrt.
Keytruda has been shown to be effective in treating patients with melanoma and non-small cell lung cancer.
Zdravilo Keytruda se je izkazalo kot učinkovito pri zdravljenju bolnikov z melanomom in nedrobnoceličnim pljučnim rakom.
KEYTRUDA has not been studied in patients with moderate or severe hepatic impairment (see section 5.2).
Pri bolnikih z zmerno ali hudo okvaro jeter zdravilo KEYTRUDA ni raziskano (glejte poglavje 5.2).
KEYTRUDA has not been studied in patients with severe renal impairment (see section 5.2).
Pri bolnikih s hudo okvaro ledvic zdravilo KEYTRUDA ni raziskano (glejte poglavje 5.2).
Keytruda is a cancer medicine used to treat adults with:
Zdravilo Keytruda je zdravilo za zdravljenje raka, ki se uporablja pri odraslih bolnikih:
KEYTRUDA is a humanised monoclonal antibody which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2.
Zdravilo KEYTRUDA je humanizirano monoklonsko protitelo, ki se veže na receptor programirane celične smrti 1 (PD-1) in blokira njegovo interakcijo z ligandi PD-L1 in PD-L2.
Keytruda is available as a powder that is made up into a solution for infusion (drip) into a vein.
Zdravilo Keytruda je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
KEYTRUDA is for single use only.
Zdravilo KEYTRUDA je samo za enkratno uporabo.
KEYTRUDA is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen.
Zdravilo KEYTRUDA je indicirano za zdravljenje lokalno napredovalega ali metastatskega nedrobnoceličnega pljučnega raka (NSCLC - non-small cell lung carcinoma) pri odraslih, ki imajo tumorje z ekspresijo PD-L1 in so bili predhodno zdravljeni z vsaj eno shemo kemoterapije.
Keytruda is specifically for lung tumours that produce a protein known as PD-L1.
Zdravila Keytruda je namenjeno posebej za zdravljenje pljučnih tumorjev, ki proizvajajo beljakovino, imenovano PD-L1.
KEYTRUDA should be permanently discontinued:
Zdravljenje z zdravilom KEYTRUDA je treba trajno ukiniti:
KEYTRUDA should not to be used in children and adolescents below 18 years of age.
Zdravila KEYTRUDA se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
Keytruda was also effective in the larger group of patients with lung cancer, including those whose tumours were not strongly positive for PD-L1.
Zdravilo Keytruda je bilo učinkovito v večji skupini bolnikov z rakom pljuč, vključno s tistimi, v tumorjih katerih niso bile ugotovljene velike količine beljakovina PD-L1.
KEYTRUDA works by helping your immune system fight your cancer.
Zdravilo KEYTRUDA deluje tako, da imunskemu sistemu pomaga premagovati raka.
Kg Premix/tonne feed
Kg predmešanice/tono krme
KGF receptors are known to be expressed on the lens of the eye.
Znano je, da so receptorji KGF eksprimirani v očesni leči.
Ki values in human liver microsomes were 27, 7.5 and 7.9 μmol/L, respectively.
Vrednosti Ki v mikrosomih človeških jeter so bile 27, 7,5 oziroma
kidney and urinary problems including impairment of kidney function, blood in the urine and urinary disturbances
obolenja sečil, vključno z okvarjenim delovanjem ledvic, krvjo v urinu in motnjami uriniranja
Kidney biopsy specimens revealed a significant increase in the fraction of normal glomeruli and a significant decrease in the fraction of glomeruli with mesangial widening in patients treated with Replagal in contrast to the patients treated with placebo.
Pri bolnikih, zdravljenih z zdravilom Replagal, so vzorci biopsije ledvic pokazali pomembno povečanje deleža normalnih glomerulov in pomembno zmanjšanje deleža glomerulov z mezangialno razširitvijo v primerjavi z bolniki, ki so prejemali placebo.
kidney cancer that is advanced or has spread to other organs. certain forms of soft tissue sarcoma a type of cancer that affects the supportive tissues of the body.
raka ledvic, ki je napredoval ali se je razširil v druge organe. določenih vrst sarkoma mehkih tkiv; to je vrsta raka, ki prizadene podporna tkiva telesa.
Kidney changes were observed after repeated oral administration of dimethyl fumarate in mice, rats, dogs, and monkeys.
Po ponavljajočem se dajanju dimetilfumarata mišim, podganam, psom in opicam so opazili spremembe na ledvicah.
kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system;
ledvične spremembe so se kazale kot blago zvečanje sečnine in kreatinina v serumu ter hiperplazija/hipertrofija jukstaglomerulnega aparata, kar je neposredna posledica interakcije med irbesartanom in sistemom renin-angiotenzin
kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system;
ledvične spremembe so se kazale kot blago zvečanje sečnine in kreatinina v serumu ter hiperplazija/hipertrofija jukstaglomerulnega aparata, kar je neposredna posledica interakcije med irbesartanom in sistemom renin-angiotenzin;
kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system;
ledvične spremembe, ki so se kazale kot blago povečanje sečnine in kreatinina v serumu ter hiperplazija/hipertrofija jukstaglomerulnega aparata, kar je neposredna posledica interakcije med irbesartanom in reninsko-angiotenzinskim sistemom;
Kidney damage is the major side effect of Vistide treatment.
Glavni neželeni učinek zdravljenja z zdravilom Vistide je okvara ledvic.
Kidney damage with low blood cell counts (thrombocytopaenic purpura/haemolytic uraemic syndrome)
Okvara ledvic z znižanimi koncentracijami krvničk (trombocitopenična purpura/hemolitično- uremični sindrom)
Kidney damage with low blood platelets and low red blood cell counts, with or without rash (haemolytic uraemic syndrome)
okvara ledvic z znižano koncentracijo krvnih ploščic in znižano koncentracijo rdečih krvničk, z izpuščajem ali brez njega (hemolitično-uremični sindrom),
kidney disease
bolezen ledvic
kidney disease
bolezen ledvic,
Kidney disease
Ledvična bolezen
Kidney disease
ledvična bolezen,
kidney disease
če imate obolenje ledvic;
Kidney disease (renal failure).
bolezen ledvic (ledvična odpoved),
Kidney disease (such as anti-GBM disease)
Bolezen ledvic (kot je bolezen zaradi prisotnih protiteles proti glomerulni bazalni membrani – »anti-GBM bolezen«)
Kidney disease or kidney transplant
ledvična bolezen ali ledvični presadek
Kidney disease or kidney transplant.
Bolezen ledvic ali presaditev ledvice.
Kidney disease or kidney transplant.
ledvično bolezen ali ledvični presadek,
Kidney disease or kidney transplant.
ledvično bolezen ali presajeno ledvico,
Kidney disease or kidney transplant.
Ledvično bolezen ali presajeno ledvico.
Kidney disease or kidney transplant.
ledvično bolezen ali so vam presadili ledvico,
kidney disease or problems
bolezen ledvic ali težave z ledvicami
Kidney disease patients
Ledvični bolniki
Kidney disease.
Ledvična bolezen.
Kidney disease.
Ledvična bolezen;
kidney disorder, abnormal kidney function tests, foamy urine tiredness, chills
bolezni ledvic, nenormalni testi ledvične funkcije, penast urin utrujenost, mrzlica
kidney disorder, blood in urine, difficulties or pain when urinating (dysuria)
bolezni ledvic, kri v urinu, težave ali bolečine pri uriniranju (disurija),
kidney disorders confusion
bolezni ledvic zmedenost
kidney disorders  abnormal thinking
bolezni ledvic  nenormalno razmišljanje
kidney disorders, (rare – may affect up to 1 in 1,000 people): may show as blood in the urine (your urine may be red or tea-coloured), or as swelling in your legs or feet.
bolezni ledvic (redki – pojavijo se lahko pri največ 1 od 1.000 bolnikov): lahko se pokažejo kot kri v urinu (urin je rdeče barve ali barve čaja) ali kot otekanje nog ali stopal.
Kidney failure
ledvična odpoved;
kidney failure
odpoved delovanja ledvic
kidney failure severe vision loss
ledvična odpoved, hudo poslabšanje vida.
Kidney failure – common
ledvična odpoved – pogosto
kidney failure,
ledvična odpoved,
Kidney failure, blood or protein in the urine
odpoved ledvic, kri ali beljakovine v urinu
kidney failure, high blood pressure, heart attack, diabetes; night sweats.
ledvična odpoved, zvišan krvni tlak, srčni infarkt, sladkorna bolezen nočno potenje
Kidney failure, inflammation of kidneys
odpoved ledvic, vnetje ledvic
kidney failure, kidney stones, difficult discharge of urine, frequent or excessive passage of urine, sometimes at night
odpovedovanje ledvic, ledvični kamni, oteženo izločanje urina, pogosto ali zvečano uriniranje, včasih tudi ponoči
Kidney failure, reduced urine volume, urinary retention
odpoved ledvic, manjša količina urina, nesposobnost izločanja urina ob polnem mehurju (zastajanje urina)
Kidney failure, reduced urine volume, urinary retention.
odpoved ledvic, manjša količina urina, nesposobnost izločanja urina ob polnem mehurju (zastajanje urina)
Kidney failure, reduced urine volume, urinary retention.
Odpoved ledvic, manjša količina urina, nesposobnost izločanja urina ob polnem mehurju (zastajanje urina).
Kidney failure.
ledvična odpoved
Kidney failure.
ledvična odpoved,
Kidney failure.
odpoved ledvic
Kidney failure.
odpoved ledvic,
kidney failure;
odpoved ledvic;
Kidney function and serum potassium levels should be evaluated before initiating combined treatment with spironolactone and Angiotensin Converting Enzyme (ACE) inhibitors.
Pred začetkom kombiniranega zdravljenja s spironolaktonom in inhibitorji angiotenzin konvertirajočega encima (ACE) je treba oceniti ledvično funkcijo in nivo serumskega kalija.